Epix: PRX-00023 fails phase 3 anxiety trial

By Elaine Rigoli

Tampa, Fla., Sept. 21 - Epix Pharmaceuticals, Inc. said results from a phase 3 trial of PRX-00023, a long-acting 5-HT1A agonist, showed that the drug did not achieve a statistically significant improvement over a placebo in the primary endpoint, which was a decrease in anxiety as measured by the Hamilton Rating Scale for Anxiety.

The Lexington, Mass.-based biopharmaceutical company said the outcome was potentially impacted by a higher-than-expected response in the placebo-treated patients.

A preliminary review has indicated that PRX-00023 was well-tolerated, with a low rate of discontinuation in this study due to adverse events. Side effects, including impact on sexual function and sleep, were similar to a placebo, according to a company news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.